ArticleACS medicinal chemistry letters2020
Challenges and Opportunities for Drug Discovery in Developing Countries: The Example of Cutaneous Leishmaniasis.
Article in ACS medicinal chemistry letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The global prevalence of antibiotic self-medication among the adult population: systematic review and meta-analysis.Systematic reviews · 2025Pooled it
- Colombian Contributions Fighting Leishmaniasis: A Systematic Review on Antileishmanials Combined with Chemoinformatics Analysis.Molecules (Basel, Switzerland) · 2020Pooled it
- Barriers and Facilitators to Conducting Clinical Trials in Developing Countries: A Systematic Review.Journal of racial and ethnic health disparities · 2026Review
- AI-powered drug discovery for neglected diseases: accelerating public health solutions in the developing world.Journal of global health · 2025Article
- Innovating Leishmaniasis Treatment: A Critical Chemist's Review of Inorganic Nanomaterials.ACS infectious diseases · 2024Review
- Forging a Future Free from Neglected Tropical Diseases.ACS medicinal chemistry letters · 2024Article
- Techniques and Strategies in Drug Design and Discovery.International journal of molecular sciences · 2024Article
- Article
- Burden of neglected tropical diseases and access to medicine and diagnostics in Ethiopia: a scoping review.Systematic reviews · 2023Article
- Antileishmanial Activity ofPlants (Basel, Switzerland) · 2023Article
- Green Approach: ''A Forwarding Step for Curing Leishmaniasis-A Neglected Tropical Disease''.Frontiers in molecular biosciences · 2021Review
- Indole: The After Next Scaffold of Antiplasmodial Agents?Drug design, development and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.